Surrozen (NASDAQ:SRZN) & Whitehawk Therapeutics (NASDAQ:WHWK) Financial ComparisonDefense World · Oct 12, 2026
Whitehawk Therapeutics, Inc. (NASDAQ:WHWK) Stock Has Consensus Target Price of $8.33 According to BrokeragesDefense World · Oct 8, 2026
Whitehawk Therapeutics Presents Real-World Analyses Supporting MUC16 as a Durable ADC Target in Ovarian Cancer at IGCS 2026PRNewsWire · Oct 1, 2026
Analysts Set Whitehawk Therapeutics, Inc. (NASDAQ:WHWK) Price Target at $8.20Defense World · Sep 16, 2026
Whitehawk Therapeutics, Inc. (WHWK) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeeking Alpha · Sep 15, 2026
Whitehawk Therapeutics Presents Real-World Analyses Supporting PTK7 as a Durable ADC Target in EGFR Wild-Type Non-Small Cell Lung Cancer at WCLC 2026GuruFocus · Sep 13, 2026Whitehawk Therapeutics, Inc., a clinical-stage oncology therapeutics company that develops technologies to establish tumor biology for cancer treatments. It provides three next generation antibody drug conjugates (ADC) portfolio to treat cancer. The company was formerly known as Aadi Bioscience, Inc. and changed its name to Whitehawk Therapeutics, Inc. in August 2021.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 6, 2026 | -$0.30 | -$0.20 | Beat |
| May 7, 2026 | -$0.36 | -$0.32 | Beat |
| Mar 12, 2026 | -$0.55 | -$0.34 | Beat |
| Nov 6, 2025 | -$0.51 | -$0.26 | Beat |
| Aug 7, 2025 | $0.49 | -$0.76 | Miss |
| May 8, 2025 | -$0.46 | $1.83 | Beat |